For instance, several KDM5A inhibitors have demonstrated promising outcomes in anti-cancer (Vinogradova et al. 2016), and there is also a KDM5A inhibitor, GS-5801, which has entered phase 1 clinical trials for chronic hepatitis B (Gilmore et al. 2017). This evidence concerns the gene KDM5A and cancer.